Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells

We compared the early effects of FK506 on clinical severity, interleukin‐2 (IL‐2) production by phytohemagglutinin‐stimulated peripheral blood mononuclear cells (PBMs), and serum levels of acetylcholine receptor antibodies between myasthenia gravis (MG) patients with elevated (>1250 pg/ml, n = 9)...

Full description

Saved in:
Bibliographic Details
Published in:Muscle & nerve 2003-02, Vol.27 (2), p.245-248
Main Authors: Utsugisawa, Kimiaki, Nagane, Yuriko, Yonezawa, Hisashi, Obara, Daiji, Kondoh, Ryushi, Tohgi, Hideo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Autoantibodies - blood
Biological and medical sciences
Female
FK506
Humans
Immunomodulators
Immunosuppressive Agents - administration & dosage
interleukin-2
Interleukin-2 - metabolism
Leukocytes, Mononuclear - immunology
Leukocytes, Mononuclear - metabolism
Male
Medical sciences
Middle Aged
myasthenia gravis
Myasthenia Gravis - drug therapy
Myasthenia Gravis - immunology
peripheral blood mononuclear cells
Pharmacology. Drug treatments
Receptors, Cholinergic - immunology
severity
Severity of Illness Index
Tacrolimus - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared the early effects of FK506 on clinical severity, interleukin‐2 (IL‐2) production by phytohemagglutinin‐stimulated peripheral blood mononuclear cells (PBMs), and serum levels of acetylcholine receptor antibodies between myasthenia gravis (MG) patients with elevated (>1250 pg/ml, n = 9) or normal (
ISSN:0148-639X
1097-4598
DOI:10.1002/mus.10285